VANCOUVER, April 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the
Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research
collaborators will make a poster presentation at the Association for
Research in Vision and Ophthalmology 2014 Annual Meeting. The Meeting
is being held from May 4th - 8th, 2014 in Orlando, Florida.
"The data being presented outlines patient demographics and baseline
characteristics of each arm of the phase two iDEAL study, as well as
the trial design and objectives," said Peter Hnik, MD, Chief Medical
Officer of iCo Therapeutics. "The poster provides a great context to
the upcoming phase two study's primary data at month eight and
secondary data at month 12."
"More treatment options are needed for individuals with diabetic macular
edema" said Helen Nickerson, Ph. D., Senior Scientific Program Manager
for Complications Therapies at JDRF. "JDRF is pleased to collaborate
in the iDEAL study and grateful to the investigators, physicians and
patients involved. We eagerly anticipate results from this important
The poster, titled "Demographics and Baseline Characteristics of the
iDEAL Study: A Randomized, Multi-center, Phase II Study of the safety,
Tolerability, and Bioactivity of Repeated Intravitreal Injections of
iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser
Photocoagulation in the Treatment of Diabetic Macular Edema with
Involvement of the FoveAL Center" is being presented by Dr. Quan Dong
Nguyen et al and will be presented from 11:00 am ET - 12:45 pm ET on
Monday, May 5. The poster presents the design, demographics, and
baseline characteristics of the iDEAL Study, as well as the
inclusion/exclusion criteria and characteristics by randomized
JDRF is the leading global organization funding type 1 diabetes (T1D)
research. JDRF's goal is to progressively remove the impact of T1D
from people's lives until we achieve a world without T1D. JDRF
collaborates with a wide spectrum of partners and is the only
organization with the scientific resources, regulatory influence, and a
working plan to better treat, prevent, and eventually cure T1D. As the
largest charitable supporter of T1D research, JDRF is currently
sponsoring $568 million in scientific research in 17 countries. For
more information, please visit www.jdrf.org.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or
generics by employing reformulation and delivery technologies for new
or expanded use indications. The Company has exclusive worldwide rights
to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and
iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2
clinical studies for DME. With Phase 2 clinical history, iCo-008 is
targeted for the treatment of keratoconjunctivitis and wet age-related
macular degeneration. In addition, iCo holds worldwide rights to an
oral drug delivery platform. The first platform candidate is the Oral
Amp B Delivery system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX Venture
Exchange under the symbol "ICO" and the OTCQX under the symbol "ICOTF".
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this
press release. Neither the TSX Venture Exchange nor its Regulatory
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this press release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking statements" within the meaning of applicable securities
laws. Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will," and similar references to future periods and includes, but is
not limited to, statements about the intended use of proceeds of the
Offering. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on iCo's current beliefs as well
as assumptions made by and information currently available to iCo and
relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place
undue reliance on these forward-looking statements, which are based
only on information currently available to iCo and speak only as of the
date of this press release. Due to risks and uncertainties, including
the risks and uncertainties identified by iCo in its public securities
filings and on its website, actual events may differ materially from
current expectations. iCo disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by law.
SOURCE iCo Therapeutics Inc.